A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

Summary

CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL).

Timeline

Start

2023-05-31

Primary completion

2026-11

Completion

2027-04

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “Clinical observations from three patients treated in a Phase 1 dose escalation trial of patients with B-NHL show that CLN-978 was clinically active.” cullinantherapeutics.com ↗

release “Two of the three patients experienced objective clinical benefit including one patient who experienced a complete response.” cullinantherapeutics.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CLN-978	Other / unclassified	—	—

Indications